Do arylhydroxylamine metabolites mediate idiosyncratic reactions associated with sulfonamides?

Chemical Research in Toxicology

Volumn 16, Issue 9, 2003, Pages 1035-1043

  Svensson, Craig K ^a,b  

^a WAYNE STATE UNIVERSITY   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; DAPSONE; DRUG METABOLITE; HYDROXYLAMINE; SULFONAMIDE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC THERAPY; CYTOTOXICITY; DELAYED HYPERSENSITIVITY; DRUG HYPERSENSITIVITY; EOSINOPHILIA; FEVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; LIVER TOXICITY; METABOLITE; PNEUMOCYSTIS PNEUMONIA; RASH; REVIEW; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

ANIMALS; DRUG HYPERSENSITIVITY; EVALUATION STUDIES; HUMANS; HYDROXYLAMINES; SULFONAMIDES;

HUMAN IMMUNODEFICIENCY VIRUS; PNEUMOCYSTIS CARINII;

EID: 0141625021     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx034098h     Document Type: Review

References (81)

1. Cribb, A. E., Lee, B. L., Trepanier, L. A., and Spielberg, S. P. (1996) Adverse reactions to sulphonamide and sulphonamide-trimethoprim antimicrobials: clinical syndromes and pathogenesis. Adverse Drug React. Toxicol. Rev. 15, 9-50.
2. Svensson, C. K., Cowen, E. W., and Gaspari, A. A. (2001) Cutaneous drug reactions. Pharmacol. Rev. 53, 357-379.
3. Berg, P., and Daniel, P. (1987) Co-trimoxazole-induced liver injury - an analysis of cases with hypersensitivity-like reactions. Infection 15, S259-S263.
4. Dujovne, D., Chan, C., and Zimmerman, H. (1967) Sulfonamide hepatic injury. N. Engl. J. Med. 377, 785-788.
5. Rieder, M. J., Uetrecht, J., Shear, N. H., Cannon, M., Miller, M., and Spielberg, S. P. (1989) Diagnosis of sulfonamide hypersensitivity reactions by in-vitro "rechallenge" with hydroxylamine metabolites. Ann. Intern. Med. 110, 286-289.
6. Uetrecht, J. P. (1999) New concepts in immunology relevant to idiosyncratic drug reactions: The "Danger Hypothesis" and innate immune system. Chem. Res. Toxicol. 12, 387-395.
7. Reilly, T. P., and Ju, C. (2002) Mechanistic perspectives on sulfonamide-induced cutaneous drug reactions. Curr. Opin. Allergy Clin. Immunol. 2, 307-315.
8. Pichler, W. J., Yawalkar, N., Britschgi, M., Depta, J. P. H., Strasser, I., Schmid, S., Kuechler, P., and Naisbitt, D. (2002) Cellular and molecular pathophysiology of cutaneous drug reactions. Am. J. Clin. Dermatol. 3, 229-238.
9. van der Ven, A. J. A. M., Vree, T. B., Koopmans, P. P., and van der Meer, J. W. M. (1995) Adverse reactions to co-trimoxazole in HIV infection: a reappraisal of the glutathione-hydroxylamine hypothesis. J. Antimicrob. Chemother. 37, 55-60.
10. Cucinelli, S. A., Israili, Z. H., and Dayton, P. G. (1972) Microsomal N-oxidation of dapsone as a cause of methemoglobin formation in human red cells. Am. J. Trop. Med. Hyg. 21, 322-331.
11. Israili, Z. H., Cucinell, S. A., Vaught, J., Davis, E., Lesser, J. M., and Dayton, P. G. (1973) Studies of the metabolism of dapsone in man and experimental animals: formation of N-hydroxy metabolites. J. Pharmacol. Exp. Ther. 187, 138-151.
12. Uehleke, H., and Tabarelli, S. (1973) N-hydroxylation of 4,4′-diaminodiphenylsuphone (Dapsone) by liver microsomes, and in dogs and humans. Naunyn-Schmiedeberg's Arch. Pharmacol. 278, 55-68.
13. Gordon, G. R., Murray, J. F., Peters, J. H., Gelber, R. H., and Jacobson, R. R. (1979) Studies on the urinary metabolites of dapsone in man. Int. J. Lepr. 47, 681-682.
14. May, D. G., Porter, J., Wilkinson, G. R., and Branch, R. A. (1994) Frequency distribution of dapsone N-hydroxylase, a putative probe for P4503A4 activity, in a white population. Clin. Pharmacol. Ther. 55, 492-500.
15. May, D. G., Porter, J. A., Uetrecht, J. P., Wilkinson, G. R., and Branch, R. A. (1990) The contribution of N-hydroxylation and acetylation to dapsone pharmacokinetics in normal subjects. Clin. Pharmacol. Ther. 48, 619-627.
16. Coleman, M. D., Scott, A. K., Breckenridge, A. M., and Park, B. K. (1990) The use of cimetidine as a selective inhibitor of dapsone N-hydroxylation in man. Br. J. Clin. Pharmacol. 30, 761-767.
17. Mitra, A. K., Thummel, K. E., Kalhorn, T. F., Kharasch, E. D., Unadkat, J. D., and Slattery, J. T. (1995) Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and in vivo. Clin. Pharmacol. Ther. 58, 556-566.
18. Shear, N. H., and Spielberg, S. P. (1985) In vitro evaluation of a toxic metabolite of sulfadiazine. Can. J. Physiol. Pharmacol. 63, 1370-1372.
19. Rieder, M. J., Uetrecht, J., Shear, N. H., and Spielberg, S. P. (1988) Synthesis and in vitro toxicity of hydroxylamine metabolites of sulfonamides. J. Pharmacol. Exp. Ther. 244, 724-728.
20. Cribb, A. E., and Spielberg, S. P. (1990) Hepatic microsomal metabolism of sulfamethoxazole to the hydroxylamine. Drug Metab. Dispos. 18, 784-787.
21. Cribb, A. E., and Spielberg, S. P. (1992) Sulfamethoxazole is metabolized to the hydroxylamine in humans. Clin. Pharmacol. Ther. 51, 522-526.
22. van der Ven, A. J., Mantel, M. A., Vree, T. B., Koopmans, P. P., and van der Meer, J. W. (1994) Formation and elimination of sulphamethoxazole hydroxylamine after oral administration of sulphamethoxazole. Br. J. Clin. Pharmacol. 38, 147-150.
23. van der Ven, A. J., Vree, T. B., van Ewijk-Beneken Kolmer, E. W., Koopmans, P. P., and van der Meer, J. W. (1995) Urinary recovery and kinetics of sulphamethoxazole and its metabolites in HIV-seropositive patients and healthy volunteers after a single oral dose of sulphamethoxazole. Br. J. Clin. Pharmacol. 39, 621-625.
24. Mitra, A. K., Thummel, K. E., Kalhorn, T. F., Kharasch, E. D., Unadkat, J. D., and Slattery, J. T. (1996) Inhibition of sulfamethoxazole hydroxylamine formation by fluconazole in human liver microsomes and healthy volunteers. Clin. Pharmacol. Ther. 59, 332-340.
25. Lee, B. L., Delahunty, T., and Safrin, S. (1994) The hydroxylamine of sulfamethoxazole and adverse reactions in patients with acquired immunodeficiency syndrome. Clin. Pharmacol. Ther. 56, 184-189.
26. Lehman, D., Holohan, P., and Blair, D. (1996) Comparisons of oxidative metabolism and reductive capacity in sulfonamide-tolerant and -intolerant patients with human immunodeficiency virus. J. Clin. Pharmacol. 36, 1149-1153.
27. Shear, N. H., Spielberg, S. P., Grant, D. M., Tang, B. K., and Kalow, W. (1986) Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann. Intern. Med. 105, 179-184.
28. Rieder, M. J., Shear, N. H., Kanee, A., Tang, B. K., and Spielberg, S. P. (1991) Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions. Clin. Pharmacol. Ther. 49, 13-17.
29. Carr, A., Gross, A. S., Hoskins, J. M., Penny, R., and Cooper, D. A. (1994) Acetylation phenotype and cutaneous hypersensitivity to trimethoprim-sulphamethoxazole in HIV-infected patients. AIDS 8, 333-337.
30. Kaufmann, G., Wenk, M., Taeschner, W., Peterli, B., Gyr, K., Meyer, U., and Haefeli, W. (1996) N-Acetyltransferase 2 polymorphism in patients infected with human immunodeficiency virus. Clin. Pharmacol. Ther. 60, 62-67.
31. Smith, C., Brown, I., and Torraca, B. (1998) Acetylator status and tolerance of high-dose trimethoprim-sulfamethoxazole therapy among patients with human immunodeficiency virus. Clin. Infect. Dis. 25, 1477-1478.
32. Wolkenstein, P., Loriot, M.-A., Aractingi, S., Cabelguenne, A., Beaune, P., and Chosidow, O. (2000) Prospective evaluation of detoxification pathways as markers of cutaneous adverse reactions to sulphonamides in AIDS. Pharmacogenetics 10, 821-828.
33. Eliaszewicz, M., Flahault, A., Roujeau, J.-C., Fillet, A.-M., Challine, D., Mansouri, S., Wolkenstein, P., Aractingi, S., Penso-Assathiany, D., Maslo, C., Bourgault-Villada, I., Chosidow, O., and Caumes, E. (2002) Prospective evaluation of risk factors of cutaneous drug reactions to sulfonamides in patients with AIDS. J. Am. Acad. Dermatol. 47, 40-46.
34. O'Neil, W. M., MacArthur, R. D., Farrough, M. J., Doll, M. A., Fretland, A. J., Hein, D. W., Crane, L. R., and Svensson, C. K. (2002) Acetylator phenotype and genotype in HIV-infected patients with and without sulfonamide hypersensitivity. J. Clin. Pharmacol. 42, 613-619.
35. Alfirevic, A., Stalford, A. C., Vilar, F. J., Wilkins, E. G. L., Park, B. K., and Pirmohamed, M. (2003) Slow acetylator phenotype and genotype in HIV-positive patients with sulphamethoxazole hypersensitivity. Br. J. Clin. Pharmacol. 55, 158-165.
36. Wolkenstein, P., Carriere, V., Charue, D., Bastuji-Garin, S., Revuz, J., Roujeau, J. C., Beaune, P., and Bagot, M. (1995) A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome. Pharmacogenetics 5, 255-258.
37. Lee, B. L., Wong, D., Benowitz, N. L., and Sullam, P. M. (1993) Altered patterns of drug metabolism in patients with acquired immunodeficiency syndrome. Clin. Pharmacol. Ther. 53, 529-535.
38. O'Neil, W. M., Drobitch, R. K., MacArthur, R. D., Farrough, M. J., Doll, M. A., Fretland, A. J., Hein, D. W., Crane, L. R., and Svensson, C. K. (2000) Acetylator phenotype and genotype in patients infected with HIV: discordance between methods for phenotype determination and genotype. Pharmacogenetics 10, 171-182.
39. Vree, T. B., Hekster, Y. A., Baars, A. M., Damsma, J. E., and van der Kleijn, E. (1978) Pharmacokinetics of sulphamethoxazole in man: Effects of urinary pH and urine flow on metabolism and renal excretion of sulphamethoxazole and its metabolite N4-acetylsulphamethoxazole. Clin. Pharmacokinet. 3, 319-329.
40. Bozkurt, A., Basci, N. E., Isimer, A., Tuncer, M., Erdal, R., and Kayaalp, S. O. (1990) Sulphamethoxazole acetylation in fast and slow acetylators. Int. J. Clin. Pharmacol. Ther. Toxicol. 28, 164-166.
41. Cribb, A. E., Nakamura, H., Grant, D. M., Miller, M. A., and Spielberg, S. P. (1993) Role of polymorphic and monomorphic human arylamine N-acetyltransferases in determining sulfamethoxazole metabolism. Biochem. Pharmacol. 45, 1277-1282.
42. Hanson, A., Melander, A., and Wahlin-Boll, E. (1981) Acetylator phenotype: a comparison of the isoniazid and dapsone tests. Eur. J. Clin. Pharmacol. 20, 233-234.
43. Gelber, R., Peters, J., Gordon, G., Glazko, A., and Levy, L. (1971) The polymorphic acetylation of dapsone in man. Clin. Pharmacol. Ther. 12, 225-238.
44. Bluhm, R., Adedoyin, A., McCarver, D., and Branch, R. (1999) Development of dapsone toxicity in patients with inflammatory dermatoses: Activity of acetylation and hydroxylation of dapsone as risk factors. Clin. Pharmacol. Ther. 65, 598-605.
45. Cribb, A. E., Spielberg, S. P., and Griffin, G. P. (1995) N4-hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P4502C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes. Drug Metab. Dispos. 23, 406-414.
46. Gill, H. J., Tingle, M. D., and Park, B. K. (1995) N-Hydroxylation of dapsone by multiple enzymes of cytochrome P450: implications for inhibition of haemotoxicity. Br. J. Clin. Pharmacol. 40, 531-538.
47. Winter, H., Wang, Y., and Unadkat, J. (2000) CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone. Drug Metab. Dispos. 28, 865-868.
48. Gill, H., Tija, J., Kitteringham, N., Pirmohamed, M., Back, D., and Park, B. (1999) The effect of genetic polymorphisms in CYP2C9 on sulphamethoxazole N-hydroxylation. Pharmacogenetics 9, 43-53.
49. Pirmohamed, M., Alfirevic, A., Vilar, J., Stalford, A., Wilkins, E. G. L., Sim, E., and Park, B. K. (2000) Association analysis of drug metabolizing enzyme gene polymorphisms in HIV-positive patients with co-trimoxazole hypersensitivity. Pharmacogenetics 10, 705-713.
50. Lehmann, D., Newman, N., and Morse, P. (1998) The effect of cimetidine on the formation of sulfamethoxazole hydroxylamine in patients with human immunodeficiency virus. J. Clin. Pharmacol. 38, 463-466.
51. Rhodes, L. E., Tingle, M. D., Park, B. K., Chu, P., Verbov, J. L., and Friedmann, P. S. (1995) Cimetidine improves the therapeutic/toxic ratio of dapsone in patients on chronic dapsone therapy. Br. J. Dermatol. 132, 257-262.
52. Coleman, M. D., Rhodes, L. E., Scott, A. K., Verbov, J. L., Friedmann, P. S., Breckenridge, A. M., and Park, B. K. (1992) The use of cimetidine to reduce dapsone-dependent methaemoglobinaemia in dermatitis herpetiformis patients. Br. J. Clin. Pharmacol. 34, 244-249.
53. Spielberg, S., Gordon, G., Blake, D., Goldstein, D., and Herlong, H. (1981) Predisposition to phenytoin hepatotoxicity assessed in vitro. N. Engl. J. Med. 305, 722-727.
54. Reilly, T. P., MacArthur, R. D., Farrough, M. J., Crane, L. R., Woster, P. M., and Svensson, C. K. (1999) Is hydroxylamine-induced cytotoxicity a valid marker for hypersensitivity reactions to sulfamethoxazole in HIV-infected individuals? J. Pharmacol. Exp. Ther. 291, 1356-1364.
55. Wolkenstein, P., Charue, D., Laurent, P., Revuz, J., Roujeau, J. C., and Bagot, M. (1995) Metabolic predisposition to cutaneous adverse drug reactions. Role in toxic epidermal necrolysis caused by sulfonamides and anticonvulsants. Arch. Dermatol. 131, 544-551.
56. Rieder, M. J., Krause, R., and Bird, I. A. (1995) Time-course of toxicity of reactive sulfonamide metabolites. Toxicology 95, 141-146.
57. Neuman, M. G., Malkiewicz, I. M., and Shear, N. H. (2000) A novel lymphocyte toxicity assay to assess drug hypersensitivity syndromes. Clin. Biochem. 33, 517-524.
58. Pohl, L. R., Satoh, H., Christ, D. D., and Kenna, J. G. (1988) The immunologic and metabolic basis of drug hypersensitivities. Annu. Rev. Pharmacol. Toxicol. 28, 367-387.
59. Park, B. K., Pirmohamed, M., and Kitteringham, N. R. (1998) Role of drug disposition in drug hypersensitivity: A chemical, molecular, and clinical perspective. Chem. Res. Toxicol. 11, 969-988.
60. Cribb, A. E., Nuss, C. E., Alberts, D. W., Lamphere, D. B., Grant, D. M., Grossman, S. J., and Spielberg, S. P. (1996) Covalent binding of sulfamethoxazole reactive metabolites to human and rat liver subcellular fractions assessed by immunochemical detection. Chem. Res. Toxicol. 9, 500-507.
61. Reilly, T. P., Lash, L. H., Doll, M. A., Hein, D. W., Woster, P. M., and Svensson, C. K. (2000) A role for bioactivation and covalent binding within epidermal keratinocytes in sulfonamide-induced cutaneous drug reactions. J. Invest. Dermatol. 114, 1164-1173.
62. Naisbitt, D. J., Gordon, S. F., Pirmohamed, M., Burkhart, C., Cribb, A. E., Pichler, W. J., and Park, B. K. (2001) Antigenicity and immunogenicity of sulphamethoxazole: demonstration of metabolism-dependent haptenation and T-cell proliferation in vivo. Br. J. Pharmacol. 133, 295-305.
63. Manchanda, T., Hess, D., Dale, L., Ferguson, S. G., and Rieder, M. J. (2002) Haptenation of sulfonamide reactive metabolites to cellular proteins. Mol. Pharmacol. 62, 1011-1026.
64. Meekins, C. V., Sullivan, T. J., and Gruchalla, R. S. (1994) Immunochemical analysis of sulfonamide drug allergy: identification of sulfamethoxazole-substituted human serum proteins. J. Allergy Clin. Immunol. 94, 1017-1024.
65. Gruchalla, R., Pesenko, R., Do, T., and Skiest, D. (1998) Sulfonamide-induced reactions in desensitized patients with AIDS - The role of covalent protein haptenation by sulfamethoxazole. J. Allergy Clin. Immunol. 101, 371-378.
66. Cribb, A. E., Pohl, L. R., Spielberg, S. P., and Leeder, J. S. (1997) Patients with delayed-onset sulfonamide hypersensitivity reactions have antibodies recognizing endoplasmic reticulum luminal proteins. J. Pharmacol. Exp. Ther. 282, 1064-1071.
67. Daftarian, M. P., Filion, L. G., Cameron, W., Conway, B., Roy, R., Tropper, F., and Diaz-Mitoma, F. (1995) Immune response to sulfamethoxazole in patients with AIDS. Clin. Diagn. Lab. Immunol. 2, 199-204.
68. Warrington, R., Sauder, P., and McPhillips, S. (1983) Lymphocyte transformation studies in suspected hypersensitivity to trimethoprim-sulphamethoxazole. Clin. Allergy 13, 235-240.
69. Schnyder, B., Burkhart, C., Schnyder-Frutig, K., von Greyerz, S., Naisbitt, D. J., Pirmohamed, M., Park, B. K., and Pichler, W. J. (2000) Recognition of sulfamethoxazole and its reactive metabolites by drug-specific CD4+ T cells from allergic individuals. J. Immunol. 164, 6647-6654.
70. Schnyder, B., Mauri-Hellweg, D., Zanni, M., Bettens, F., and Pichler, W. J. (1997) Direct, MHC-dependent presentation of the drug sulfamethoxazole to human alphabeta T cell clones. J. Clin. Invest. 100, 136-141.
71. von Greyerz, S., Zanni, M., Frutig, K., Schnyder, B., Burkhart, C., and Pichler, W. (1999) Interaction of sulfonamide derivatives with the TCR of sulfamethoxazole-specific human αβ+ T cell clones. J. Immunol. 162, 595-602.
72. Mauri-Hellweg, D., Bettens, F., Mauri, D., Brander, C., Hunziker, T., and Pichler, W. J. (1995) Activation of drug-specific CD4+ and CD8+ T cells in individuals allergic to sulfonamides, phenytoin, and carbamazepine. J. Immunol. 155, 462-472.
73. Kalish, R., LaPorte, A., Wood, J., and Johnson, K. (1994) Sulfonamide-reactive lymphocytes detected at very low frequency in the peripheral blood of patients with drug-induced eruptions. J. Allergy Clin. Immunol. 94, 465-472.
74. Farrell, J., Naisbitt, D. J., Drummond, N. S., Depta, J. P. H., Vilar, F. J., Pirmohamed, M., and Park, B. K. (2003) Characterization of sulfamethoxazole and sulfamethoxazole metabolite-specific T-cell responses in animals and man. J. Pharmacol. Exp. Ther. 306, 229-237.
75. Kimber, I. (1996) in Toxicology of Contact Hypersensitivity (Kimber, I., and Maurer, T., Eds.) pp 127-139, Taylor & Francis, London.
76. Garrigue, J.-L., Nicolas, J.-F., Fraginals, R., Benezra, C., Bour, H., and Schmitt, D. (1994) Optimization of the mouse ear swelling test for in vivo and in vitro studies of weak contact sensitizers. Contact Dermatitis 30, 231-237.
77. Choquet-Kastylevsky, G., Santolaria, N., Tedone, R., Aujoulat, M., and Descotes, J. (2001) Induction of delayed-type hypersensitivity to sulfamethoxazole in mice: role of metabolites. Toxicol. Lett. 119, 183-192.
78. Zanni, M., von Greyerz, S., Schnyder, B., Brander, K., Frutig, K., Hari, Y., Valitutti, S., and Pichler, W. (1998) HLA-restricted, processing- and metabolism-independent pathway of drug recognition by human αβ T lymphocytes. J. Clin. Invest. 102, 1591-1598.
79. Delomenie, C., Grant, D., Mathelier-Fusade, P., Jacomet, C., Leynadier, F., Jacqz-Aigrain, E., Rozenbaum, W., Krishnamoorthy, R., and Dupret, J.-M. (1994) N-Acetylation genotype and risk of severe reactions to sulphonamides in AIDS patients. Br. J. Clin. Pharmacol. 38, 581.
80. Riley, R. J., Cribb, A. E., and Spielberg, S. P. (1991) Glutathione transferase mu deficiency is not a marker for predisposition to sulphonamide toxicity. Biochem. Pharmacol. 42, 696-698.
81. Carr, A., Tindall, B., Penny, R., and Cooper, D. A. (1993) In vitro cytotoxicity as a marker of hypersensitivity to sulphamethoxazole in patients with HIV. Clin. Exp. Immunol. 94, 21-25.